Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. (Q38451680)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

title

Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

Simon D Shorvon

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

5

Lynn Kramer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

2

Elinor Ben-Menachem

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

Bernhard J. Steinhoff

1

object named as

Bernhard J Steinhoff

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Andrew Satlin

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

David Squillacote

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

Haichen Yang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

Jin Zhu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

Antonio Laurenza

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

publication date

10 May 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Epilepsia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1481-1489

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

Antiepileptic drug therapy the story so far

1 March 2020

cites work

1 reference

A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus

21 January 2018

1 reference

Refractory epilepsy: clinical overview

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

21 January 2018

1 reference

Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304

21 January 2018

1 reference

Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305

21 January 2018

1 reference

Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs

21 January 2018

1 reference

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

21 January 2018

1 reference

Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy

21 January 2018

1 reference

Tolerability and safety of perampanel: two randomized dose-escalation studies.

21 January 2018

1 reference

Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

21 January 2018

1 reference

Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

21 January 2018

1 reference

Revisiting AMPA receptors as an antiepileptic drug target

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/EPI.12212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23663001 AND SRC:MED&resulttype=core&format=json

1 March 2020

1 reference